Leighla Smith, DO
Family Medicine · Lansing, MINPI 1912566522
Payments from drug & device makers
Across 67 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$314
- Lilly USA, LLC$133
- Novo Nordisk$87
- GSK$82
- Otsuka America Pharmaceutical, Inc.$81
- Axsome Therapeutics, Inc.$53
- plus $404 from 16 others
What the payments were for
- Food & beverage$1,154100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $314 |
| Lilly USA, LLC | 3 | $133 |
| Novo Nordisk | 4 | $87 |
| GSK | 5 | $82 |
| Otsuka America Pharmaceutical, Inc. | 3 | $81 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| AstraZeneca | 3 | $48 |
| Bayer | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Exact Sciences | 2 | $29 |
| Alkermes, Inc. | 1 | $29 |
| Nevro Corp. | 1 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $28 |
| Microtransponder, Inc. | 1 | $24 |
| Grifols USA, LLC | 1 | $24 |
| Mylan Specialty L.p. | 1 | $23 |
| Pfizer | 1 | $21 |
| Eisai Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| OWP Pharmaceuticals, Inc. | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$1,154 in reported general payments places this provider in the 70th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 108 | $110,710 |
| TrulicityDulaglutide | 67 | $104,343 |
| EliquisApixaban | 126 | $94,032 |
| JanuviaSitagliptin Phosphate | 80 | $88,883 |
| JardianceEmpagliflozin | 78 | $84,771 |
| MounjaroTirzepatide | 49 | $52,905 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $38,520 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $37,765 |
| FarxigaDapagliflozin Propanediol | 36 | $36,653 |
| XareltoRivaroxaban | 12 | $18,643 |
| InvokanaCanagliflozin | 20 | $16,994 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 32 | $16,368 |
| Tiotropium Bromide | 15 | $13,858 |
| EntrestoSacubitril/Valsartan | 18 | $13,133 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $12,783 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $133 | $157,248116 claims |
| Novo NordiskOzempic | $87 | $110,710108 claims |
| PfizerEliquis | $21 | $94,032126 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $82 | $63,643106 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $48 | $56,81266 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Lansing
- Farhan BhattiLansing$230K
- David WeismantelLansing$180K
- Laurie RozekLansing$86K
- Amy TrinhLansing$19K
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.